晚期NSCLC患者接受纳武利尤单抗治疗早期使用全身皮质类固醇的研究
该回顾性研究分析了210例接受纳武利尤单抗治疗的晚期NSCLC患者,发现31%的患者同时使用全身皮质类固醇。在纳武利尤单抗治疗前30天内使用皮质类固醇的患者,中位纳武利尤单抗周期数为2,未使用者为5(p=0.002);中位总生存期分别为4.3个月和11个月(HR=2.30,95%CI 1.27-4.16,p=0.006)。结论提示早期使用皮质类固醇可能降低纳武利尤单抗的临床获益。
要点
- 31%接受纳武利尤单抗治疗的NSCLC患者同时使用全身皮质类固醇。
- 前30天内使用皮质类固醇者纳武利尤单抗周期数更少(中位2 vs 5,p=0.002)。
- 前30天内使用皮质类固醇者总生存期更短(中位4.3 vs 11个月,HR=2.30,p=0.006)。
核心结论
- 在接受纳武利尤单抗治疗的晚期NSCLC患者中,早期使用全身皮质类固醇与更少的纳武利尤单抗周期数和更短的总生存期相关,提示临床获益可能降低。
研究设计与样本
- 回顾性队列研究,纳入克利夫兰诊所210例接受纳武利尤单抗治疗的NSCLC患者,分析全身皮质类固醇使用与客观结局(纳武利尤单抗周期数和总生存期)的关联。
主要发现
- 66例(31%)患者在纳武利尤单抗治疗期间同时接受全身皮质类固醇。
- 常见适应症包括活动性或治疗后脑转移后遗症(27%)和慢性阻塞性肺疾病或其他呼吸系统疾病(21%)。
- 早期暴露于皮质类固醇(纳武利尤单抗治疗前30天内)的患者(12%,n=25)中位纳武利尤单抗周期数为2,未暴露者为5(p=0.002)。
- 前30天内使用皮质类固醇者中位总生存期为4.3个月,未使用者为11个月(多因素分析HR=2.30,95%CI 1.27-4.16,p=0.006)。
临床怎么用
- 对于接受纳武利尤单抗治疗的晚期NSCLC患者,应谨慎评估全身皮质类固醇的使用时机和必要性,尤其是在治疗早期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Checkpoint inhibitors augment the immune system's natural surveillance mechanisms and have increasing applications in NSCLC. Immunosuppressive corticosteroids are also frequently used in this population to treat unwanted inflammation. In view of this mechanistic opposition, we investigated the interaction between nivolumab and corticosteroids in patients with advanced NSCLC. METHODS: A retrospective review of the charts of 210 patients with NSCLC who were treated with nivolumab at the Cleveland Clinic was performed. Use of systemic corticosteroids (equivalent to >10 mg of prednisone/d) during nivolumab therapy was associated with the objective outcomes number of nivolumab cycles and overall survival. RESULTS: In all, 66 patients (31%) received concurrent systemic corticosteroids during nivolumab therapy. The most common indications included sequelae from active or treated brain metastases (27%) and chronic obstructive pulmonary disease or other respiratory disease (21%). For patients with early exposure to steroids (within the first 30 days of nivolumab therapy) (12% [n=25]), the median number of nivolumab cycles was 2, compared with five cycles in patients who were not exposed to corticosteroids (p = 0.002). The median overall survival time for patients who received steroids during the first 30 days was 4.3 months, compared with 11 months for patients who did not receive steroids (hazard ratio for death = 2.30, 95% confidence interval: CI 1.27-4.16, p = 0.006 in multivariate analysis). CONCLUSION: Nearly one-third of patients with NSCLC treated with nivolumab were prescribed concurrent corticosteroids during the course of nivolumab therapy. Patients exposed to corticosteroids during the first cycle of nivolumab received fewer total cycles of nivolumab, suggesting decreased clinical benefit, and they had shorter overall survival.
引用
- Scott SC, Pennell NA. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. J Thorac Oncol. 2018. PMID: 29935305. doi:10.1016/j.jtho.2018.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。